During our previous careers at Pfizer Inc. our primary focus was on the discovery
and development of novel therapeutic agents to treat a variety of CNS disorders.
Our experience with Geodon / Zeldox (TM) during the R&D stages has enabled us
to design and evaluate new chemical matter that may eventually lead to new
therapies for depression, Alzheimer's disease and other related human disorders.

Screening of our compounds in this area is offered through the Psychotherapeutic
Drug Screening Program (PDSP) at the University of North Carolina, Chapel Hill.
With funding provided by the National Institutes of Mental Health (NIMH), Dr.
Bryan Roth and his colleagues test each compound in a variety of receptor and
enzyme assays. Recently, we have identified compounds that have high affinity for
Kappa and Delta opioid and Sigma 1 / 2 receptors in the CNS.

We are currently exploring additional examples from this class to identify the
optimal compound(s) for advanced testing with the goal of selecting a candidate
for study in animal models of depression and/or mania.


Human African Trypanosomiasis (HAT) is a disease caused by a blood-borne
parasite and transmitted by tsetse fly bites to humans and cattle in central Africa.
Infection rates vary, but estimates during epidemic periods have ranged as high as
500,000 cases per year, resulting in tens of thousands of deaths as the parasite
passes into the brain of patients, causing neurological disorders and - if left
untreated - death. Treatment options are limited, not readily available and
generally not well tolerated.

Since 2011, we have partnered with scientists  St. Louis University (SLU) in St.
Louis, MO, to discover and evaluate novel treatments for HAT. Using our
knowledge and experience in the design and development of CNS targeted drugs,
we have identified several distinct chemical templates which can be exploited to
create safer and more efficacious medications, especially for Stage 2 HAT
patients. SLU is collaborating with MediSynergics to assess the potency of these
compounds against a number of
Trypanosoma brucei strains in an effort to select
the best compounds for development and human efficacy studies.

In 2016 we were awarded a 2-year, SBIR Phase 1 grant, totaling $600,000, by the
National Institute for Allergy and Infectious Diseases (NIAID), part of the National
Institutes of Health (NIH). With this generous grant we have significantly increased
our efforts into finding better treatment options for HAT.   Our lead candidate
MS-107 has recently undergone in vivo studies directed by Dr. Kojo Mensa-
Wilmot of the University of Georgia, Athens, GA (UGA), a recognized leader in
the discovery of infectious diseases treatments.

MediSynergics, LLC has filed numerous patent applications with the United States
Patent and Trademark Office (USPTO) for the use of our novel compounds in the
treatment of patients with CNS and parasitic diseases.  To date, ten US Patents
have been granted to MediSynergics, while an eleventh application has recently
been approved.
Simarro PP1, Cecchi G, Paone M, et al.  "The Atlas of human African
trypanosomiasis: a contribution to global mapping of neglected tropical
diseases."  Int. J. Health Geogr. 2010 Nov 1;9:57.
doi: 10.1186/1476-072X-9-57.
Photomicrograph of T. brucei
parasite in human blood sample.
Tsetse fly